Objectives: We conducted a multicenter phase II study to evaluate the clinical effi cacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine as fi rst-line treatment of metastatic breast cancer patients. Methods: We enrolled 58 patients, 52% of whom had received a previous anthracycline-containing chemotherapy. The treatment schedule was: docetaxel 35 mg/m 2 and gemcitabine 800 mg/m 2 i.v. on days 1, 8,15 every 28 days. Results: All patients were assessable for toxicity and 56 for effi cacy. Overall response rate was 64.3% with 16.1% of complete responses and 48.2% of partial responses. Median survival was 22.10 months (95% CI: 15.53–28.67) and median time to tumor progression was 13.6 months (95% CI: 10.71–16.49). The most common hematological toxicity was neutropenia (no febrile neutropenia), which occurred in 28 patients (48.3%) but grade 3–4 in only 8 patients (14%). Alopecia, the most common nonhematological toxicity, occurred in 20 (34.5%) patients, but only 5 patients (8.6%) experienced grade 3 alopecia. Conclusion: The activity of docetaxel and gemcitabine in metastatic breast cancer is confirmed. The promising results of the employed schedule,in agreement with other published studies, need to be further confirmed within a phase III study.
|Data di pubblicazione:||2005|
|Titolo:||“Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study”|
|Autori:||PALMERI, S; VAGLICA, M; SPADA, S; FILIPPELLI, G; FARRIS, A; PALMERI, L; MASSIDDA, B; MISINO, A; FERRAU', F; COMELLA, G; LEONARDI, V; CONDEMI, G; MANGIAMELI, A; DE CATALDIS, G; MACALUSO, MC; CAJOZZO, M; IANNITTO, E; DANOVA, M|
|Tipologia:||Articolo su rivista|
|Citazione:||PALMERI, S., VAGLICA, M., SPADA, S., FILIPPELLI, G., FARRIS, A., PALMERI, L., et al. (2005). “Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study”. ONCOLOGY, 68 (4-6), 438-445.|
|Digital Object Identifier (DOI):||10.1159/000086986|
|Appare nelle tipologie:||01 - Articolo su rivista|